RSS

Relypsa

Veltassa, a sodium-free potassium binder treatment for hyperkalaemia, has been approved for marketing by the European Commission (EC) with the first launches planned for the end of this year or early next year. more

News

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Relypsa, have announced a partnership to commercialise Relypsa's investigational medicine for the treatment of hyperkalaemia more

News